US8740602052
© PR Newswire
16.12.2025
TAK
LISTED
NYSE
British Columbia reimburses FRUZAQLA™ (fruquintinib capsules) for the treatment of metastatic colorectal cancer (mCRC)
News Preview
TORONTO, Dec. 16, 2025 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by BC Cancer as a treatment option for adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates, for available standard...
Themefolio
Profiler
Peergroup
© BusinessWire
06.12.2025
TAK
LISTED
NYSE
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
News Preview
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. T...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
TAK
LISTED
NYSE
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
News Preview
Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
03.11.2025
TAK
LISTED
NYSE
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
News Preview
Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, QDENGA®▼(Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). These data, including an exploratory analysis of a booster dose, confirm the favorable benefit and r...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
30.10.2025
TAK
LISTED
NYSE
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
News Preview
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2025 (six months ended Sep 30, 2025) and updated its full-year outlook.
Takeda chief executive officer, Christophe Weber, commented:
“Takeda’s fiscal year 2025 first half results are consistent with our expectations for core business progress in this...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2025
TAK
LISTED
NYSE
HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
News Preview
Takeda (TSE:4502/NYSE:TAK) today announced that the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older, as prescribed, who are prescribed HYQVIA® [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase]. The dedicated devices allow HYQVIA, a facilitated subcuta...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2025
TAK
LISTED
NYSE
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
News Preview
Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into a license and collaboration agreement with Innovent Biologics (HKEX: 01801) for the development, manufacturing and commercialization of two late-stage oncology medicines, IBI363 and IBI343, worldwide outside of Greater China.* IBI363 is being evaluated in non-small cell lung and c...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
TAK
LISTED
NYSE
20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries
News Preview
Takeda (TOKYO:4502/NYSE: TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to building climate-resilient health systems in low- and middle-income countries around the world. Amid rising temperatures and extreme weather events...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2025
TAK
LISTED
NYSE
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
News Preview
Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical company to transport its products between Europe and the U.S. using VELA’s first-of-its-kind sailing cargo trimaran. VELA designed and will operate a fleet of new generation sailing cargo vessels, powered...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
TAK
LISTED
NYSE
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
News Preview
Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), during multiple oral presentations at the World Sleep 2025 Congress in Singapore beginning at...
Themefolio
Profiler
Peergroup
© BusinessWire
06.09.2025
TAK
LISTED
NYSE
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
News Preview
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI® [von Willebrand factor (Recombinant)], expanding the indication to include routine prophylaxis to reduce the frequency of bleeding episodes in adults with von Willebrand Diseas...
Themefolio
Profiler
Peergroup
© PR Newswire
28.08.2025
TAK
LISTED
NYSE
Takeda's FRUZAQLA™ (fruquintinib) publicly reimbursed in Quebec for the treatment of metastatic colorectal cancer (mCRC)
News Preview
TORONTO, Aug. 28, 2025 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by Régie de l'assurance maladie (RAMQ) for people in Quebec, under certain criteria, as a treatment for adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
30.07.2025
TAK
LISTED
NYSE
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
News Preview
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVANSE significantly impacting revenue and Core Operating Profit in line with company expectations for the quarter. The company expects these impacts to moderate in future quarters....
Themefolio
Profiler
Peergroup
© BusinessWire
21.07.2025
TAK
LISTED
NYSE
Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration
News Preview
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHubTM and HyHubTM Duo, devices for patients 17 years of age and older that allow HYQVIA® [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase] to be transferred from vials without using a needle in a...
Themefolio
Profiler
Peergroup
© BusinessWire
14.07.2025
TAK
LISTED
NYSE
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
News Preview
Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861), a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist, in narcolepsy type 1 (NT1). NT1 is caused by the loss of orexin-produc...
Themefolio
Profiler
Peergroup
© BusinessWire
30.06.2025
TAK
LISTED
NYSE
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
News Preview
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for peopl...
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
TAK
LISTED
NYSE
Takeda Announces New Assignments of Directors
News Preview
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Shareholders, held in Osaka today.
Takeda's Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure transparency and objectivity. An e...
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
TAK
LISTED
NYSE
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
News Preview
Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. The decision...
Themefolio
Profiler
Peergroup
© BusinessWire
01.06.2025
TAK
LISTED
NYSE
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
News Preview
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a late-breaking oral...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
TAK
LISTED
NYSE
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
News Preview
Takeda (TSE:4502/NYSE:TAK) today announced that applications are now open for its Innovators in Science Award. This prestigious global award, originally launched in 2016, celebrates groundbreaking research with a focus on emerging scientific leaders who are advancing the frontiers of scientific discovery and fostering innovation that has the poten...
Themefolio
Profiler
Peergroup
© BusinessWire
14.05.2025
TAK
LISTED
NYSE
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
News Preview
Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficien...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
TAK
LISTED
NYSE
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress
News Preview
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management.
Takeda has built a high-value late-stage pipe...
Themefolio
Profiler
Peergroup
© BusinessWire
05.05.2025
TAK
LISTED
NYSE
BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers
News Preview
BioLife Plasma Services, part of Takeda (TSE:4502/NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S. network of plasma donation centers. The new Adaptive Nomogram is used on the Aurora Xi Plasmapheresis System, which is in more than half of BioLife's U.S. plasma donation centers. This...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
TAK
LISTED
NYSE
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education
News Preview
See the full release at Takeda.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250430215346/en/...
Themefolio
Profiler
Peergroup
© BusinessWire
03.03.2025
TAK
LISTED
NYSE
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
News Preview
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study m...
Themefolio
Profiler
Peergroup
© PR Newswire
24.02.2025
TAK
LISTED
NYSE
Die Europäische Arzneimittelagentur (EMA) hat eine zusätzliche Option zur subkutanen Verabreichung von TAKHZYRO® (Lanadelumab) für Patienten ab 12 Jahren mit wiederkehrenden Attacken des hereditären Angioödems (HAE) genehmigt
News Preview
TAKHZYRO-Injektionslösung in einem 2-ml-Fertigpen ist jetzt zur Erleichterung der subkutanen Verabreichung bei jugendlichen (ab 12 Jahren) und erwachsenen Patienten mit HAE zugelassen.1 Die Option des vorgefüllten Pens wurde entwickelt, um eine individualisierte Behandlung von jugendlichen und erwachsenen HAE-Patienten zu ermöglichen. In der EU i...
Themefolio
Profiler
Peergroup
© PR Newswire
24.02.2025
TAK
LISTED
NYSE
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
News Preview
TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult HAE Patients.In the EU, TAKHZYRO is Approved for Rou...
Themefolio
Profiler
Peergroup
© PR Newswire
24.02.2025
TAK
LISTED
NYSE
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
News Preview
TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult HAE Patients.In the EU, TAKHZYRO is Approved for Rou...
Themefolio
Profiler
Peergroup
© BusinessWire
30.01.2025
TAK
LISTED
NYSE
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
News Preview
Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026. M...
Themefolio
Profiler
Peergroup
© BusinessWire
30.01.2025
TAK
LISTED
NYSE
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
News Preview
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch Products, which delivered double-digit growth of 14.6% at CER. The company has upgraded its full year outlook for growth, reflecting strong year-to-da...
Themefolio
Profiler
Peergroup
© BusinessWire
27.12.2024
TAK
LISTED
NYSE
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
News Preview
Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an incr...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
TAK
LISTED
NYSE
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
News Preview
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. The company has upgraded its full year forecasts and Management Guidance to reflect stronger than anticipated first-half performance...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2024
TAK
LISTED
NYSE
Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
News Preview
Takeda (TOKYO:4502/NYSE:TAK) and Boston Medical Center (BMC) today announced a new collaboration focused on identifying innovative solutions that can reduce hard-to-abate greenhouse gas (GHG) emissions in the health care sector. The collaboration between Takeda and BMC aims to reduce the GHG emissions caused by disposal of regulated medical waste,...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2024
TAK
LISTED
NYSE
Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
News Preview
Takeda (TSE:4502/NYSE:TAK) will present additional data from the Phase 2b trials (TAK-861-2001,TAK-861-2002) and long-term extension (LTE) study (TAK-861-2003) of TAK-861 in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society (ESRS), being held September 24-27, 2024 in...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2024
TAK
LISTED
NYSE
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
News Preview
Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to improving health systems resiliency in low and middle-income countries around the world. This commitment demonstrates Takeda’s focus on tackling syste...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
